Adamas Pharmaceuticals, Inc. (ADMS)
Stock Price:
$3.78 USD
1.17 (44.83%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.89 +0.11 (2.91%) Aug 7, 7:59 PM
Key Info
| Market Cap |
106.44M |
| Revenue (ttm) |
57.45M |
| Net Income (ttm) |
-77.87M |
| Shares Out |
28.16M |
| EPS (ttm) |
-3.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$3.78 |
| Previous Close |
$2.61 |
| Change ($) |
1.17 |
| Change (%) |
44.83% |
| Day's Open |
3.20 |
| Day's Range |
3.19 - 4.14 |
| Day's Volume |
5,946,311 |
| 52-Week Range |
1.90 - 7.78 |
More Stats
| Market Cap |
106.44M |
| Enterprise Value |
139.92M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.16M |
| Float |
20.33M |
| EPS (basic) |
-2.78 |
| EPS (diluted) |
-3.31 |
| FCF / Share |
-2.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
931,410 |
| Short Ratio |
1.56 |
| Short % of Float |
3.06% |
| Beta |
1.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1.85 |
| PB Ratio |
n/a |
| Revenue |
57.45M |
| Operating Income |
-64.20M |
| Net Income |
-77.87M |
| Free Cash Flow |
-66.50M |
| Net Cash |
-33.48M |
| Net Cash / Share |
-1.19 |
| Gross Margin |
90.80% |
| Operating Margin |
-111.74% |
| Profit Margin |
-122.50% |
| FCF Margin |
-115.75% |
| ROA |
-26.12% |
| ROE |
-383.56% |
| ROIC |
-29.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
7 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
1 |
| Sell |
0 |
Price Target
$9.17*
(142.59% upside)
Low
3.00
Current: $3.78
High
20.00
Target: 9.17
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 54.64 | 34.05 | 0.57 | 0.57 | 1.92 | 55.85 | 71.10 | 37.47 |
| Revenue Growth | 60.48% | 5862.52% | -0.17% | -70.15% | -96.57% | -21.45% | 89.73% | - |
| Gross Profit | 52.17 | 33.41 | 0.55 | 0.57 | 1.92 | 55.85 | 71.10 | 37.47 |
| Operating Income | -92.24 | -115 | -87.93 | -60.98 | -57.44 | 18.51 | 57.02 | 19.95 |
| Net Income | -105 | -131 | -89.49 | -60.06 | -51.80 | 8.97 | 33.07 | 11.44 |
| Shares Outstanding | 27.68 | 26.89 | 22.56 | 21.71 | 18.11 | 14.84 | 9.51 | 9.49 |
| Earnings Per Share | -3.80 | -4.87 | -3.97 | -2.77 | -2.86 | 0.53 | 2.99 | 1.17 |
| EPS Growth | - | - | - | - | - | -82.27% | 155.56% | - |
| Operating Cash Flow | -80.78 | -104 | -66.83 | -48.07 | -47.21 | 27.79 | 26.80 | 51.96 |
| Capital Expenditures | -0.02 | -1.06 | -1.26 | -1.62 | -1.40 | -1.29 | -0.17 | -0.02 |
| Free Cash Flow | -80.80 | -105 | -68.09 | -49.69 | -48.61 | 26.51 | 26.63 | 51.94 |
| Cash & Equivalents | 133 | 211 | 173 | 114 | 107 | 122 | 85.61 | 62.96 |
| Total Debt | 136 | 119 | 103 | - | - | - | - | 4.00 |
| Net Cash / Debt | -3.38 | 91.75 | 70.80 | 114 | 107 | 122 | 85.61 | 58.96 |
| Assets | 162 | 235 | 186 | 142 | 129 | 161 | 86.22 | 64.30 |
| Liabilities | 163 | 145 | 120 | 10.29 | 12.56 | 14.12 | 10.46 | 40.19 |
| Book Value | -0.89 | 89.89 | 66.13 | 132 | 116 | 147 | 56.61 | 4.97 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adamas Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
136 |
| CEO |
Neil F. McFarlane |
Stock Information
| Ticker Symbol |
ADMS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: ADMS |
| IPO Date |
April 10, 2014 |
Description
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.